comparemela.com

Latest Breaking News On - Cybin inc - Page 1 : comparemela.com

Numinus Wellness Inc : Numinus Clarifies Disclosures

Vancouver, British Columbia (Newsfile Corp. - June 7, 2024) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company advancing traditional and innovative

British columbiaUnited statesUnited kingdomCraig macphailPaul thielkingNuminus wellness incCybin incNuminus network doBritish columbia newsfile corpCanadian centre for psychedelic healingCedar clinical researchNuminus networkCybin embarkGroundbreaking journeyPioneering phaseMajor depressive

Numinus Clarifies Disclosures

Numinus Wellness Inc. , a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, wishes to.

British columbiaUnited statesUnited kingdomCraig macphailPaul thielkingNuminus wellness incNuminus networkNuminus network doCanadian centre for psychedelic healingCedar clinical researchCybin incBritish columbia newsfile corpCybin embarkGroundbreaking journeyPioneering phaseMajor depressive

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment - ATAI Life Sciences (NASDAQ:ATAI), Cybin (AMEX:CYBN)

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.

Elizabeth joniakCybin incDrug administrationElizabeth joniak grantGoing on with mindmed and psychedelic

Cybin Inc : Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024

- Amir Inamdar, Chief Medical Officer, to appear on panel discussions on June 5 and June 8 - - Ellen James, Director, Clinical Development, to present abstract titled "SPL026 (DMT fumarate) in combination

Noord hollandUnited kingdomUnited statesKellen jamesGabriel fahelSamir inamdarExchange commissionHealth canadaClinical developmentInterdisciplinary conference on psychedelic researchDrug administrationCybin incChief medical officerMajor depressiveInterdisciplinary conferencePsychedelic research

Cybin s (CYBN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Cybin (NYSE:CYBN – Free Report) in a research report report published on Thursday, Benzinga reports. The brokerage currently has a $5.00 price objective on the stock. HC Wainwright also issued estimates for Cybin’s FY2029 earnings at $0.26 EPS. Cybin Stock Down 0.6 % NYSE:CYBN opened at […]

Cybin incIkarian capitalInvestment company incFree reportStock downGet free reportCybin daily

vimarsana © 2020. All Rights Reserved.